This question tests renal transport disorders from amino acid transporter mutations. The principle is that loss-of-function in reabsorptive transporters increases urinary excretion, leading to precipitation and stones. The dibasic amino acid transporter mutation impairs cystine reabsorption, elevating urinary cystine and forming stones. This accounts for the kidney stones and hexagonal crystals. Choice B is incorrect as it suggests decreased cystine from increased affinity, confusing loss-of-function with gain. For similar cases, link transport defects to solute loss. Verify with urinalysis findings like crystals.

This question tests lysosomal storage diseases from glucosidase mutations. The principle is that compartment-specific enzyme defects impair degradation, causing substrate-filled lysosomes and organ dysfunction. The acid alpha-glucosidase deficiency blocks lysosomal glycogen breakdown, leading to accumulation and muscle weakness. This explains cardiomyopathy and weakness in Pompe disease. Choice B is wrong because it confuses lysosomal with cytosolic pathways. In analogous scenarios, emphasize subcellular sites. Verify with biopsy accumulation patterns.

This question examines the effects of active-site mutations in lysosomal storage disorders. The principle is that mutations altering catalytic residues impair enzyme function without affecting protein synthesis or localization, leading to substrate accumulation in compartments. The point mutation in the catalytic residue reduces the lysosomal enzyme's k_cat, causing substrate buildup despite normal protein levels and trafficking. This fits the neurodegeneration from lysosomal storage, as activity is low but abundance is normal. Choice A is incorrect because it implies increased affinity accelerating breakdown, confusing catalytic efficiency with substrate binding. To solve similar problems, distinguish between mutations affecting catalysis versus stability. Confirm by evaluating if symptoms align with compartment-specific accumulation.

This question assesses knowledge of glycogen storage diseases caused by mutations in gluconeogenic enzymes. The key principle is that defects in enzymes required for glucose release from the liver lead to intracellular trapping of glucose precursors, shunting them into alternative metabolic routes. Here, the glucose-6-phosphatase deficiency prevents dephosphorylation of glucose-6-phosphate, causing its accumulation in the liver and increased flux through glycolysis to lactate. This explains the hepatomegaly, hypoglycemia, and elevated lactate, as the liver cannot export glucose during fasting. Choice D is wrong because it assumes glucose-6-phosphate cannot enter glycolysis, ignoring that the defect is downstream, allowing glycolytic entry but blocking glucose release. For similar problems, locate the metabolic bottleneck and predict buildup of intermediates. Consider compensatory pathways like increased lactate production to confirm the diagnosis.

This question tests anaplerotic pathway defects from carboxylase mutations. The principle is that blocks in converting odd-chain precursors to TCA intermediates cause organic acid accumulation and metabolic acidosis. The propionyl-CoA carboxylase deficiency impairs conversion to methylmalonyl-CoA, reducing succinyl-CoA entry and building up propionyl-derived acids. This results in failure to thrive, diarrhea, and anion gap acidosis. Choice B is wrong because it claims increased succinyl-CoA from acetyl-CoA, confusing the pathway direction. In analogous cases, trace carbon flow to the TCA cycle. Confirm with elevated specific metabolites like propionate.

This question tests knowledge of carbohydrate metabolism disorders from transferase mutations. The principle is that blocks in sugar conversion pathways cause accumulation of phosphorylated intermediates and reduction to polyols in tissues like the lens. The GALT deficiency prevents galactose-1-phosphate exchange to UDP-glucose, leading to galactose and its phosphate buildup, with aldose reductase converting galactose to galactitol causing cataracts. This accounts for the neonatal symptoms after milk ingestion. Choice C is incorrect as it proposes reversal of GALT, which is not possible due to thermodynamic barriers. For similar disorders, identify toxic accumulations and alternative pathways. Check consistency with dietary triggers like lactose.

This question evaluates redox metabolism defects from dehydrogenase mutations. The principle is that impaired NADPH production reduces glutathione regeneration, increasing oxidative damage susceptibility. The G6PD mutation limits NADPH in RBCs, impairing antioxidant defenses and causing hemolysis under stress. This explains drug-triggered symptoms in affected individuals. Choice B is wrong because it claims increased NADPH, misstating the deficiency effect. In comparable scenarios, connect NADPH to redox buffering. Confirm with triggers like oxidants for verification.

This question assesses porphyrias from decarboxylase mutations. The principle is that heme synthesis defects cause porphyrin intermediate buildup, leading to photosensitivity from reactive species generation. The uroporphyrinogen decarboxylase deficiency accumulates uroporphyrinogen, oxidizing to porphyrins that cause skin lesions upon light exposure. This explains the photosensitivity and urine darkening. Choice B is misleading because it claims decreased porphyrins with increased heme, reversing the block effect. In related problems, identify the porphyrin pathway step. Check for light-dependent symptoms to confirm.

This question tests propionate metabolism disorders from mutase mutations. The principle is that blocks prevent TCA anaplerosis, accumulating upstream acids like methylmalonic. The methylmalonyl-CoA mutase deficiency reduces succinyl-CoA formation, building up methylmalonyl metabolites. This fits the elevated methylmalonic acid. Choice B is incorrect as it suggests reaction reversal, which is not thermodynamically favored. For similar problems, trace anaplerotic paths. Check metabolite patterns for confirmation.

This question tests understanding of enzyme defects causing metabolic blocks with upstream metabolite accumulation. Galactose-1-phosphate uridyltransferase (GALT) catalyzes the conversion of galactose-1-phosphate to UDP-galactose in the Leloir pathway of galactose metabolism. When GALT activity is reduced due to a missense mutation, galactose-1-phosphate cannot be efficiently converted to UDP-galactose, causing it to accumulate in tissues, particularly hepatocytes. The correct answer (A) accurately describes this metabolic block and accumulation pattern, which explains the hepatomegaly and liver enzyme elevation seen in classic galactosemia. Choice B incorrectly reverses the reaction direction, as GALT catalyzes the forward reaction, not the reverse. To identify the correct answer in similar questions, focus on the directionality of the enzymatic reaction and recognize that enzyme defects cause substrate accumulation upstream of the block, not downstream product accumulation.